--- title: "Biomedicine has been listed as a \"new emerging pillar industry,\" and tracking indices may have long-term industrial trends. The ICBCCS CNI HK Connect Innovative Drugs ETF (159217) helps investors to easily position themselves" type: "News" locale: "en" url: "https://longbridge.com/en/news/280737470.md" description: "Biomedicine has been listed as an emerging pillar industry, signaling industrial upgrading. The R&D capabilities of innovative drugs have been recognized, and the commercialization prospects are promising. A certain pharmaceutical company has been acquired by an overseas giant, validating the NewCo business model. Brokers believe that concerns in the BD market will ease, and the probability of BD scale shrinking is low. As industry profitability improves, commercialization will become the core of future pricing. The CNI HK Connect Innovative Drug Index may welcome a Davis double-hit opportunity, and the ICBCCS Innovative Drug ETF (159217) will help investors lay out low-cost investments" datetime: "2026-03-27T06:13:10.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280737470.md) - [en](https://longbridge.com/en/news/280737470.md) - [zh-HK](https://longbridge.com/zh-HK/news/280737470.md) --- # Biomedicine has been listed as a "new emerging pillar industry," and tracking indices may have long-term industrial trends. The ICBCCS CNI HK Connect Innovative Drugs ETF (159217) helps investors to easily position themselves Editor: Ye Feng In this year's government work report, biomedicine has been listed for the first time alongside integrated circuits, aerospace, and the low-altitude economy as an "emerging pillar industry," which is seen as a strong policy signal for accelerated industrial upgrading and high-quality development. At the same time, the cooperation in innovative drug overseas continues to deepen, with China's innovative drug R&D capabilities recognized by multinational pharmaceutical companies, leading to explosive growth in BD transactions and a continuously improving commercialization outlook. Wind data shows that as of the morning of March 27, the innovative drug sector has strengthened. On the industry news front, recently, a pharmaceutical company was acquired by an overseas biopharmaceutical giant, validating the NewCo business model. Unlike the BD model, under the NewCo model, the licensor may receive some cash flow even when the pipeline is still in the relatively early stages and has not yet reached the BD threshold, while retaining future equity appreciation and revenue sharing, which is expected to become an important opportunity for the commercialization and revaluation of early pipelines. Some brokerages have indicated that the market's previous concerns about the sustainability of BD may gradually ease. The probability of a significant shrinkage in BD scale is low, as the demand for "patent cliffs" from overseas MNCs is urgent, and there has been no significant contraction in China's BD transaction demand since 2026. Industry insiders have stated that with the marginal easing of geopolitical conflicts and some alleviation of liquidity concerns, as the trajectory of the industry shifts from losses to profit improvement becomes clearer, BD is beginning to transition from "news stimulus" to "profit source," with commercialization volume making "product revenue" likely to become the core anchor for future industry pricing. The China National Securities Hong Kong Connect Innovative Drug Index, which has long-term industry trends and is valued at relatively low levels, may welcome a Davis double-hit opportunity! The China National Securities Hong Kong Connect Innovative Drug Index (abbreviated as: Hong Kong Connect Innovative Drug, code: 987018) mainly selects constituent stocks from Hong Kong-listed companies whose main business involves innovative drug R&D, production, etc., aiming to reflect the operational characteristics of listed companies in the innovative drug field within the Hong Kong Connect scope. According to the data, the Hong Kong Connect Innovative Drug ETF ICBC (159217), as an on-market investment tool closely tracking the China National Securities Hong Kong Connect Innovative Drug Index, has a management fee rate of 0.40% and a custody fee rate of 0.07%, helping investors seize the development opportunities in the innovative drug industry at a low cost. For opportunities in innovative drugs on the Sci-Tech Innovation Board, investors can pay attention to the Sci-Tech Pharmaceutical ETF ICBC (588860). Fund fee description: The on-market trading fees for the Hong Kong Connect Innovative Drug ETF ICBC and the Sci-Tech Pharmaceutical ETF ICBC are subject to the actual charges by the securities company. Subscription fees are charged during the fund subscription process, and when investors subscribe for fund shares, the subscription and redemption agent brokerage may charge a commission not exceeding 0.5%, which includes related fees charged by the securities exchange, registration agency, etc. Redemption fees are charged during the fund redemption process, and when investors redeem fund shares, the subscription and redemption agent brokerage may charge a commission not exceeding 0.5%, which includes related fees charged by the securities exchange, registration agency, etc. The management fee rate for the Hong Kong Connect Innovative Drug ETF ICBC is 0.4% per year, and the custody fee rate is 0.07% per year; the management fee rate for the Sci-Tech Pharmaceutical ETF ICBC is 0.45% per year, and the custody fee rate is 0.07% per year Risk Warning: The fund manager manages and utilizes the fund's assets in accordance with the principles of diligence, honesty, and prudence, but does not guarantee that the fund will achieve profits or provide minimum returns. Past performance of the fund does not indicate future performance, and the performance of other funds managed by the fund manager does not constitute a guarantee of the fund's performance. The China Southern CNI HK Connect Innovative Drug ETF and the ICBCCS CNI HK Connect Innovative Drugs ETF are equity funds, with risks and returns higher than those of mixed funds, bond funds, and money market funds. Both are index funds that primarily adopt a full replication strategy to track the performance of the underlying index, exhibiting risk-return characteristics similar to those of the underlying index and the stock market it represents. The China Southern CNI HK Connect Innovative Drug ETF will also invest in stocks eligible for the Hong Kong Stock Connect, and will bear exchange rate risks and unique risks arising from differences in the investment environment, investment targets, market systems, and trading rules under the Hong Kong Stock Connect mechanism. Investing in ETFs involves risks such as fluctuations in the underlying index and deviations between the fund's investment portfolio returns and the underlying index returns. Investing in equity funds carries a significant risk of return volatility. Funds carry risks, and investors should carefully read the "Fund Contract," "Prospectus," "Fund Product Information Summary," and updates before investing in the fund. Based on a comprehensive understanding of the product situation, fee structure, charging standards of various sales channels, and after considering the suitability opinions of sales institutions, investors should choose investment products that suit their own risk tolerance. Fund investment should be approached with caution. Daily Economic News ### Related Stocks - [159297.CN](https://longbridge.com/en/quote/159297.CN.md) - [159217.CN](https://longbridge.com/en/quote/159217.CN.md) ## Related News & Research - [Universal Digital Inc. Announces Termination of ETF Partnership Agreement | LFGMF Stock News](https://longbridge.com/en/news/286616540.md) - [23:54 ETBD&J Expands Current Pro Bono Offerings with New Pro Bono Division](https://longbridge.com/en/news/286660141.md) - [Peter Menziuso Named EVP and President, BD Interventional | BDX Stock News](https://longbridge.com/en/news/286757706.md) - [Guardian Ultra-Short U.S. T-Bill Fund ETF declares $0.1448 dividend](https://longbridge.com/en/news/286471588.md) - [BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System | BDX Stock News](https://longbridge.com/en/news/287204464.md)